These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 33843899)
1. The importance of exposing patients with metastatic colorectal cancer to all treatment options. Loupakis F Clin Adv Hematol Oncol; 2021 Jan; 19 Suppl 3(1):3-5. PubMed ID: 33843899 [No Abstract] [Full Text] [Related]
5. Options for patients with metastatic colorectal cancer who progress after second-line therapy. Marshall JL Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):2-4. PubMed ID: 31730589 [No Abstract] [Full Text] [Related]
6. The importance of keeping patients with metastatic colorectal cancer on treatment through the management of adverse events. Grothey A Clin Adv Hematol Oncol; 2020 Oct; 18 Suppl 16(10):15-19. PubMed ID: 33843851 [No Abstract] [Full Text] [Related]
7. New possibilities in chemotherapy for colorectal cancer. Bekradda M; Cvitkovic E Ann Oncol; 1999; 10 Suppl 6():105-11. PubMed ID: 10676561 [No Abstract] [Full Text] [Related]
8. The handling of metastatic colorectal cancer. Fornarini G; Guglielmi A; Sobrero A Ann Oncol; 2005; 16 Suppl 2():ii141-3. PubMed ID: 15958445 [No Abstract] [Full Text] [Related]
9. Recent advances in the treatment of metastatic colorectal cancer in Taiwan. Lin YL; Yeh KH; Cheng AL J Formos Med Assoc; 2011 Jan; 110(1):1-3. PubMed ID: 21316006 [No Abstract] [Full Text] [Related]
10. [First-line chemotherapy for unresectable and metastatic colorectal cancer]. Satoh T Gan To Kagaku Ryoho; 2014 Nov; 41(11):1372-5. PubMed ID: 25577805 [No Abstract] [Full Text] [Related]
11. [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer]. Kawakami H; Satoh T; Nakagawa K Nihon Rinsho; 2011 Apr; 69 Suppl 3():439-45. PubMed ID: 22214001 [No Abstract] [Full Text] [Related]
12. Chemotherapy and immunotherapy in metastatic colorectal cancer. Frati L; Codacci-Pisanelli G N Engl J Med; 2009 May; 360(20):2134-5; author reply 2135-6. PubMed ID: 19445031 [No Abstract] [Full Text] [Related]
13. FOLFOXIRI and bevacizumab for metastatic colorectal cancer. Cremolini C; Loupakis F; Falcone A N Engl J Med; 2015 Jan; 372(3):291-2. PubMed ID: 25587960 [No Abstract] [Full Text] [Related]
14. FOLFOXIRI and bevacizumab for metastatic colorectal cancer. Matsuoka A; Maeda O; Ando Y N Engl J Med; 2015 Jan; 372(3):291. PubMed ID: 25587962 [No Abstract] [Full Text] [Related]
15. FOLFOXIRI and bevacizumab for metastatic colorectal cancer. Haines IE N Engl J Med; 2015 Jan; 372(3):290-1. PubMed ID: 25587961 [No Abstract] [Full Text] [Related]
17. Refining the use and sequencing of third-line therapy in patients with metastatic colorectal cancer. Grothey A Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):7-14. PubMed ID: 33843905 [No Abstract] [Full Text] [Related]
19. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Marks EI; Tan C; Zhang J; Zhou L; Yang Z; Scicchitano A; El-Deiry WS Cancer Biol Ther; 2015; 16(12):1710-9. PubMed ID: 26561209 [TBL] [Abstract][Full Text] [Related]